Concord Drugs Ltd.
Snapshot View

View in App

Prices View details

28.20 +0.10 ▲0.4%

18 May 2022, 04:01:00 PM
Volume: 570

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.concorddrugs.in
Market Cap 24.66 Cr.
Enterprise Value(EV) 35.48 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 2.17 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 12.98 Trailing Twelve Months Ending 2021-12
Industry PE 28.96 Trailing Twelve Months Ending 2021-12
Book Value / Share 32.40 Trailing Twelve Months Ending 2021-12
Price to Book Value 0.87 Calculated using Price: 28.20
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 0.87 Cr. 8,743,750 Shares
FaceValue 10
Company Profile

Concord Drugs is a public limited company established in the year 1995. The company is one among selected few pharmaceutical companies in India with dedicated state of art WHO-GMP certified facility. The company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide its customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. The company has manufacturing license issued by the Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.

Concord Drugs operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products. Concord Drugs Limited has two manufacturing facilities built to comply with standards stipulated by Regulatory bodies.

Business area of the company:

Concord Drugs is engaged in developing new products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery.

Products

Concord Drugs offers products of international standards through innovations with foresight of its responsibility towards the Society at large:

  • Gastrointestinal Drug Pellets
  • Cardivascular Drug Pellets
  • Respiratory Drug Pellets
  • Pain Management Drug Pellets  
  • Anti Obesity Drug Pellets  
  • Anti Depressant Drug Pellets
  • Central Nerous System Drug Pellets  
  • Urological Drug Pellets
  • Anti - Microbial, Anti - Infective & Adjuvant Drug Pellets  
  • Taste Mask Drug Pellets/Powder 
  • Nutrition and Food Suppliment Drug Pellets
  • Anti Cholestrol Drug Pellets
  • Multi Unit Pellet System Drug Pellets (Mups) 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.36%
1 Week
+0.36%
1 Month
-8.14%
3 Month
-10.19%
6 Month
-7.84%
1 Year
-16.69%
2 Year
+73.54%
5 Year
-45.98%
10 Year

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 8.85 2.72 5.37 12.32 0.94 1.69 1.92 1.41 13.06
Return on Capital Employed (%) 6.30 7.15 11.33 15.90 8.84 7.49 6.17 6.06 15.69
Return on Assets (%) 2.93 0.79 1.41 3.28 0.30 0.40 0.43 0.47 6.08

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 14 15 13 15 19 19 23 23 27 28
Non Curr. Liab. 12 12 13 17 7 6 4 7 7 6
Curr. Liab. 15 18 28 21 29 81 56 27 16 18
Minority Int.
Equity & Liab. 41 45 54 52 56 106 83 58 50 52
Non Curr. Assets 20 21 19 16 25 14 13 12 14 14
Curr. Assets 21 23 36 37 30 92 70 46 36 38
Misc. Exp. not W/O
Total Assets 41 45 54 52 56 106 83 58 50 52

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 28 34 40 51 57 52 48 51 51 52
Other Income 0 0 0 0 0 0 0 0
Total Income 28 34 40 51 58 52 48 51 51 52
Total Expenditure -26 -31 -33 -42 -52 -47 -44 -48 -48 -46
PBIDT 2 3 7 8 6 5 4 3 3 6
Interest -1 -2 -3 -3 -2 -2 -2 -2 -1 -2
Depreciation -1 -1 -4 -3 -3 -2 -2 -1 -1 -2
Taxation 0 0 0 -1 0 0 0 0 -1 -1
Exceptional Items 4 0
PAT 1 0 1 2 0 0 0 0 3 2
Adjusted EPS 1 0 1 2 0 0 1 0 4 2

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -3 1 2 2 4 2 7 1 2 2
Cash Fr. Inv. -2 -10 -2 -1 0 -1 -2 0 -1 -4
Cash Fr. Finan. 6 8 0 -1 -4 -4 -5 -1 -2 2
Net Change 0 -1 0 0 0 -3 0 0 0 0
Cash & Cash Eqvt 1 0 0 0 0 -3 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 42.78 42.78 42.78 42.78 44.38 44.38 49.00 49.00 49.00
Public 57.22 57.22 57.22 57.22 55.62 55.62 51.00 51.00 51.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 17 May 2022
Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended 31.03.2022
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Audited financial results for the quarter and year ended 31.03.2022
Fri, 06 May 2022
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Resignation of CS
Fri, 06 May 2022
Board Meeting Outcome for Resignation Of CS
Resignation of CS

Technical Scans View Details

Wed, 18 May 2022
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
High Decrease 1 Month High Decrease 1 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 215,700.21 899.00 +0.8%
Divi's Laboratories Ltd. 115,623.51 4,355.45 +1.2%
Cipla Ltd. 76,889.38 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. 65,126.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. 53,689.19 3,734.00 -2.1%
Gland Pharma Ltd. 51,396.43 3,122.95 +0.6%
Piramal Enterprises Ltd. 47,255.41 1,980.00 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.47 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 45.03 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 30.55 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 24.64 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 47.37 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 43.33 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 38.03 1,980.00 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.17 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.67 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 3.69 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 3.39 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.70 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 7.48 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.33 1,980.00 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 0.10 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,980.00 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,980.00 -0.2%